Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel or nab-paclitaxel or pemetrexed (Bristol Myers Squibb)
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to a group of distinct antineoplastic agents: paclitaxel, nab-paclitaxel, and pemetrexed. Paclitaxel and nab-paclitaxel are taxanes that function as microtubule stabilizers, promoting microtubule assembly and inhibiting depolymerization, thereby disrupting cell division and inducing apoptosis. Nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel, designed to improve drug delivery and potentially reduce solvent-related toxicities. Pemetrexed is an antifolate antimetabolite that inhibits key enzymes (thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase) involved in purine and pyrimidine synthesis, thus interfering with DNA replication and repair. These agents are widely used in the treatment of various cancers, including ovarian, breast, non-small cell lung cancer, mesothelioma, and pancreatic cancer.
- Brand names
- TaxolOnxolAbraxaneAlimtaPemfexyCiambraPemrydi RTUAxtleAnzatax
- Other names
- paclitaxelnab-paclitaxelpemetrexed
02
Targets
TUBB (Tubulin (alpha and beta subunits))GART (GAR transformylase)BCL-2 (BCL-2 family)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on paclitaxel or nab-paclitaxel or pemetrexed (Bristol Myers Squibb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel or nab-paclitaxel or pemetrexed (Bristol Myers Squibb).